Clinical endocannabinoid deficiency (CECD) is a medical theory that proposes that a deficiency of endocannabinoids is the underlying pathophysiology of migraines , fibromyalgia , and irritable bowel syndrome .[ 1] [ 2] The deficiency may sometimes start in the womb as a result of maternal obesity .[ 3]
The nature of the syndrome and existence of CECD as a clinically meaningful condition have been called into question.[ 4]
^ Russo, EB (2004). "Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?". Neuro Endocrinology Letters . 25 (1–2): 31–9. PMID 15159679 .
^ Russo, EB (2016). "Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes" . Cannabis and Cannabinoid Research . 1 (1): 154–165. doi :10.1089/can.2016.0009 . PMC 5576607 . PMID 28861491 .
^ Schlabritz-Loutsevitch, N, et al. (2016). "Fetal Syndrome of Endocannabinoid Deficiency (FSECD) in Maternal Obesity". Medical Hypotheses . 96 : 35–38. doi :10.1016/j.mehy.2016.09.021 . PMID 27959272 .
^ Cogan, PS (2020). "Practical Considerations of Hypotheses and Evidence in Cannabis Pharmacotherapy: Refining Expectations of Clinical Endocannabinoid Deficiency" . Journal of Dietary Supplements . 17 (5): 608–624. doi :10.1080/19390211.2020.1769246 . PMID 32449630 .